//fpnotebook.com/
Tenofovir
Aka: Tenofovir, Tenofovir Disoproxil, TDF, Tenofovir Alafenamide, TAF, Viread
- See Also
- Anti-Retroviral Therapy
- Nucleoside Reverse Transcriptase Inhibitor
- Preparations
- Tenofovir Disoproxil Fumarate (TDF)
- Original Tenofovir formulation and used in Stribild, Truvada and Complera
- Associated with nephrotoxicity and decreased Bone Mineral Density
- Tenofovir Alafenamide Fumarate (TAF)
- Tenofovir formulation released in 2016 and used in Genvoya, Descovy, Odefsey
- TAF appears to have less adverse Renal Function and Bone Mineral Density effects than the original TDF
- TAF is associated with greater weight gain and dyslipidemia than TDF
- Mechanism
- Nucleoside Reverse Transcriptase Inhibitor
- Adverse Effects
- See nRTI for adverse effects attributed to the class
- Renal dysfunction
- Increased Serum Creatinine
- Proteinuria
- Electrolyte abnormalities
- Glycosuria
- Hypophosphatemia
- Acute Renal Failure (1% risk)
- Associated with longer duration of therapy, advanced HIV or pre-existing renal disease
- Gastrointestinal
- Diarrhea
- Nausea or Vomiting
- Flatulence
- Miscellaneous
- Headache
- Hepatitis B flares on withdrawal of medication
- Dosing
- Dose: 300 mg orally daily
- Monitoring
- Obtain Urinalysis every 6 months when on Tenofovir Disoproxil Fumarate
- Obtain baseline Renal Function and Phosphorus, then at 2-8 weeks, and then every 3-6 months
- References
- (2016) Presc Lett 23(9)
- (2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
- Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]